Clinical genitourinary cancer最新文献

{"title":"Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching","authors":"Keita Kobayashi ,&nbsp;Hiroaki Matsumoto ,&nbsp;Shigeru Sakano ,&nbsp;Mitsutaka Yamamoto ,&nbsp;Masahiro Tsuchida ,&nbsp;Yasuhide Tei ,&nbsp;Kazuhiro Nagao ,&nbsp;Kazuo Oba ,&nbsp;Seiji Kitahara ,&nbsp;Seiji Yano ,&nbsp;Satoru Yoshihiro ,&nbsp;Yoshiaki Yamamoto ,&nbsp;Chietaka Ohmi ,&nbsp;Hirotaka Komatsu ,&nbsp;Taku Misumi ,&nbsp;Jumpei Akao ,&nbsp;Koji Shiraishi","doi":"10.1016/j.clgc.2024.102212","DOIUrl":"10.1016/j.clgc.2024.102212","url":null,"abstract":"<div><h3>Introduction</h3><p>In cases of metastatic and unresectable urothelial carcinoma with no disease progression after 4 cycles of chemotherapy, including platinum agents, treatment options include continuation of chemotherapy or switching to maintenance therapy with avelumab. This study compared the treatment outcomes of avelumab maintenance therapy with those of pembrolizumab in urothelial carcinoma using propensity score matching.</p></div><div><h3>Patients and Methods</h3><p>Between January 2017 and December 2022, 243 patients with metastatic and unresectable urothelial carcinoma were treated with either avelumab or pembrolizumab at the Yamaguchi University Hospital and its affiliated institutions. We retrospectively compared the oncological outcomes and adverse events by aligning patient characteristics and treatment backgrounds using propensity score matching.</p></div><div><h3>Results</h3><p>The analysis compared 36 cases receiving avelumab maintenance therapy after chemotherapy to 49 cases where patients, after receiving 4 courses of chemotherapy including platinum-based agents without disease progression, were subsequently administered pembrolizumab as a second-line treatment following disease progression. Using propensity score matching, 27 cases from each group were selected for comparison. From the initiation of prechemotherapy to disease progression on immune checkpoint inhibitors, the median progression-free survival was 20.7 and 23.3 months in the avelumab and pembrolizumab groups, respectively, with no statistically significant difference observed (<em>P</em> = .358). However, avelumab tended to have a lower rate of high-dose glucocorticoid treatment compared to pembrolizumab.</p></div><div><h3>Conclusion</h3><p>Progression-free survival was similar for avelumab maintenance therapy and the sequence of continued chemotherapy followed by pembrolizumab after no disease progression at four chemotherapy courses. Avelumab may require less high-dose glucocorticoid treatment, potentially enhancing safety.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102212"},"PeriodicalIF":2.3,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Markers in Identifying Pathological Complete Response Status in Muscle Invasive Bladder Cancer Patients Who Achieved Clinical Complete Response After Neoadjuvant Chemotherapy","authors":"Chengri Piao ,&nbsp;Dongmei Liu ,&nbsp;Zhen Liu ,&nbsp;Liping Shan","doi":"10.1016/j.clgc.2024.102211","DOIUrl":"10.1016/j.clgc.2024.102211","url":null,"abstract":"<div><h3>Background</h3><p>Prior research has demonstrated a discrepancy between pathologic and clinical staging in individuals with muscle-invasive bladder cancer (MIBC) following neoadjuvant chemotherapy (NAC). These findings were the major reasons for the under-usage of the bladder preservation strategy. Hence, we aim to explore the reliable markers in identifying pathological complete response (ypCR) status in MIBC patients who achieved clinical complete response (cCR) after NAC.</p></div><div><h3>Methods</h3><p>Between January 2016 and April 2023, 161 consecutive MIBC patients treated with NAC and achieved cCR were enrolled in the study. Patient clinicopathologic information was documented. Multivariate binary logistic regression was used for determining adjusted odds ratios (OR) and 95% confidence intervals (CI). It considered statistically significant when a <em>P</em> &lt; .05.</p></div><div><h3>Results</h3><p>Of the 161 MIBC patients with cCR after NAC, 64.0% (103/161) achieved ypCR after RC. The independent factors for ypCR status were the origin of MIBC (secondary vs. Primary) with odds ratios (OR) of 0.433 (<em>P</em> = .027), the pathological type (pure vs. mixed) with OR of 3.556 (<em>P</em> = .003), concurrent carcinoma in situ (yes vs. no) with OR of 0.360 (<em>P</em> = .016), and lymphovascular invasion (yes vs. no) with OR of 0.271 (<em>P</em> = .007).</p></div><div><h3>Conclusion</h3><p>This study demonstrated that primary MIBC, pure UC pathological type, absence of concurrent CIS, and LVI were significant predictors of ypCR in MIBC patients who achieved cCR after NAC and before surgery. These findings may contribute to the decision-making process of bladder preservation strategy in selected patients.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102211"},"PeriodicalIF":2.3,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142167620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France","authors":"Bryan Wong ,&nbsp;Jenny Peng ,&nbsp;Di Maria Jiang ,&nbsp;Karim Fizazi ,&nbsp;Thomas Powles ,&nbsp;Nick James ,&nbsp;Srikala S. Sridhar","doi":"10.1016/j.clgc.2024.102210","DOIUrl":"10.1016/j.clgc.2024.102210","url":null,"abstract":"<div><h3>Background</h3><p>Clinical trials are categorized as industry sponsored trials (ISTs) or investigator-initiated trials (IITs) based on the source of funding and sponsor of the trial. ISTs are usually run by pharmaceutical companies, and are primarily aimed at developing new drugs that ultimately gain regulatory approval. IITs are developed by academic investigators or cooperative groups, often sparked by a clinical need. Both are vital in advancing the field of oncology. To date, little has been published about current trends in ISTs or IITs in genitourinary (GU) oncology. The aim of this study was to assess growth trends of GU oncology ISTs and IITs in 4 countries with similar healthcare infrastructures.</p></div><div><h3>Methods</h3><p>We searched ClinicalTrials.gov for bladder, kidney, and prostate cancer trials conducted in the United States (US), Canada, France, and United Kingdom (UK) from January 2007 to December 2021. Trials were determined to be ISTs or IITs based on their funding source and sponsor. Trials were characterized based on type, purpose, phase, participants, masking, assignment, and allocation.</p></div><div><h3>Results</h3><p>Overall, 5,834 GU trials were identified, with a balanced distribution of ISTs (n = 3064, n = 52.5%) and IITs (n = 2770, 47.4%). By country, the US conducted the most GU trials (n = 3814) followed by Canada (n = 709), France (n = 677), and the UK (n = 634). Most ISTs were phase 3 trials with over 500 participants while most IITs were open-label phase 2 studies with only 20-49 participants. From 2017 onwards, there was a shift towards more ISTs, most noticeably in Canada and the UK. The COVID-19 pandemic did not have a major impact on the growth of ISTs and IITs.</p></div><div><h3>Conclusion</h3><p>The gap between ISTs and IITs continues to widen, likely driven by resource and funding challenges faced by investigators. Barriers to completing IITs need to be better understood to promote IIT development and maintain their academically driven intentions.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102210"},"PeriodicalIF":2.3,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142201808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study","authors":"Dimitra Rafailia Bakaloudi ,&nbsp;Elizabeth L. Koehne ,&nbsp;Leonidas N. Diamantopoulos ,&nbsp;Sarah K. Holt ,&nbsp;Rishi R. Sekar ,&nbsp;Fady Ghali ,&nbsp;Funda Vakar-Lopez ,&nbsp;Yaw A. Nyame ,&nbsp;Sarah P. Psutka ,&nbsp;John L. Gore ,&nbsp;Claire M. de la Calle ,&nbsp;Daniel W. Lin ,&nbsp;George R. Schade ,&nbsp;Jay J. Liao ,&nbsp;Andrew C. Hsieh ,&nbsp;Todd Yezefski ,&nbsp;Jessica E. Hawley ,&nbsp;Evan Y. Yu ,&nbsp;R. Bruce Montgomery ,&nbsp;Petros Grivas ,&nbsp;Jonathan L. Wright","doi":"10.1016/j.clgc.2024.102208","DOIUrl":"10.1016/j.clgc.2024.102208","url":null,"abstract":"<div><h3>Background</h3><p>Small cell bladder cancer (SCBC) is a rare histologic subtype with relative paucity of data regarding treatment response and outcomes. We reviewed 2 databases to compare outcomes in patients with localized SCBC treated with cystectomy versus concurrent chemoradiotherapy (CCRT). We hypothesized that survival would be similar with these therapy approaches.</p></div><div><h3>Methods</h3><p>We retrospectively reviewed our institutional and SEER-Medicare databases to identify patients with SCBC. Overall survival (OS) was determined from the date of diagnosis to last follow-up/death. For those with nonmetastatic disease, a multivariate Cox analysis was used to compare locoregional therapy with neoadjuvant chemotherapy (NAC) + cystectomy versus CCRT.</p></div><div><h3>Results</h3><p>We identified 53 patients in our institutional database and 1166 patients in SEER-Medicare with localized SCBC. Median OS (mOS) with NAC + cystectomy was 46 months (95% CI, 21-72) and 45 months (95% CI, 0-104) in the institutional and SEER-Medicare databases, respectively, whereas mOS with CCRT was 26 months (95% CI, 5-47) and 23 months (95% CI, 18-28) in the 2 series, respectively. In multivariate analysis, NAC followed by cystectomy was associated with an approximately 30% reduction in mortality compared to CCRT in both institutional and national databases but did not reach statistical significance (Institution HR 0.71, 95% CI, 0.22-2.4, <em>P</em> = .58; SEER HR 0.73, 95% CI, 0.49-1.08; <em>P</em> = .11).</p></div><div><h3>Conclusions</h3><p>SCBC is very aggressive with limited survival observed in our institutional and SEER-Medicare datasets regardless of locoregional therapy used. There is an unmet need to define the optimal locoregional therapy for nonmetastatic stage and identify novel therapeutic targets.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102208"},"PeriodicalIF":2.3,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142167735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Cytoreductive Nephrectomy in Metastatic Clear Cell Renal cell Carcinoma in the Era of immunotherapy: An Analysis of the National Cancer Database","authors":"Maroun Bou Zerdan ,&nbsp;Stephanie Niforatos ,&nbsp;Swathi Arunachalam ,&nbsp;Tamara Jamaspishvili ,&nbsp;Roger Wong ,&nbsp;Gennady Bratslavsky ,&nbsp;Joseph Jacob ,&nbsp;Jeffrey Ross ,&nbsp;Oleg Shapiro ,&nbsp;Hanan Goldberg ,&nbsp;Alina Basnet","doi":"10.1016/j.clgc.2024.102193","DOIUrl":"10.1016/j.clgc.2024.102193","url":null,"abstract":"<div><h3>Background</h3><p>The effectiveness of the clinical outcome of CN (Cytoreductive Nephrectomy) in cases of mccRCC (Metastatic Clear Cell Renal cell Carcinoma) is still uncertain despite two trials, SURTIME and CARMENA. These trials, conducted with Sunitinib as the standard treatment, did not provide evidence supporting the use of CN.</p></div><div><h3>Methods</h3><p>We queried the NCDB for stage IV mccRCC patients between the years of 2004 to 2020, who received (immunotherapy) IO with or without nephrectomy. Overall survival (OS) was calculated among three groups of IO alone, IO followed by CN (IOCN), CN followed by IO (CNIO). Cox models compared OS by treatment group after adjusting for sociodemographic, health, and facility variables.</p></div><div><h3>Results</h3><p>From 1,549,101 renal cancer cases, 7983 clear and nonclear cell renal cell carcinoma cases were identified. After adjusting for sociodemographic and health covariates, patients who received IO followed by CN or CN followed by IO had a respective 64% (adjusted Hazard Ratio [aHR] = 0.36, 95% CI = 0.30-0.43, <em>P</em> = .006] and 47% (aHR = 0.53, 95% CI = 0.49-0.56, <em>P</em> = .001) mortality risk reduction respectively compared to patients who received IO alone. Compared to White adults, individuals who identified as Black exhibited 17% higher risk mortality (aHR = 1.17, 95% CI = 1.06-1.30, <em>P</em> = .002). Patients who received CN prior to IO had a 59% associated mortality risk compared to patients who received IO followed by CN who had a lower risk, 35.7% (<em>P</em> &lt; .001).</p></div><div><h3>Conclusions</h3><p>Patients receiving CN regardless of sequence with IO did better than IO alone in this national registry-based adjusted analysis for mccRCC. Presently available data indicates that the combination of CN and IO holds promise for enhancing clinical results in patients with mRCC.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102193"},"PeriodicalIF":2.3,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142201809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fatigue Management in Advanced Prostate Cancer: Real-World Insights From Qualitative Interviews With Patients","authors":"Stephen J. Freedland ,&nbsp;Marty Chakoian ,&nbsp;Ted Wells ,&nbsp;Nader El-Chaar ,&nbsp;Alexandra Colon ,&nbsp;Dina Elsouda ,&nbsp;Agnes Hong","doi":"10.1016/j.clgc.2024.102209","DOIUrl":"10.1016/j.clgc.2024.102209","url":null,"abstract":"<div><h3>Background</h3><p>Patients with advanced prostate cancer (PC) commonly experience fatigue related to the disease itself and its treatment, which affects their quality of life. There are limited real-world data available on patients’ experiences of fatigue while receiving PC treatment and its management.</p></div><div><h3>Patients and Methods</h3><p>This was a cross-sectional, noninterventional qualitative study involving individual concept-elicitation interviews with patients in the United States. Patients with advanced PC aged ≥18 years who had experienced fatigue and were on androgen-deprivation therapy in combination with second-generation androgen receptor pathway inhibitors were interviewed and their experiences quantified.</p></div><div><h3>Results</h3><p>Of the 143 patients screened, 13 qualified and 11 completed the interview. Most patients used the term “fatigue” (<em>n</em> = 8) to describe their experiences of tiredness, exhaustion, lack of energy, and weakness. Most patients (<em>n</em> = 8) did not receive any form of educational support from their healthcare providers (HCPs), but some expressed an interest in receiving this support (pamphlets, <em>n</em> = 4; discussion with HCPs, <em>n</em> = 4; online resources, <em>n</em> = 3). Most patients (<em>n</em> = 9) self-discovered fatigue-management strategies over the course of their disease and treatment. Patients found that rigorous exercise (<em>n</em> = 5), regular naps (<em>n</em> = 2), increased rest (<em>n</em> = 3), and a healthy diet (<em>n</em> = 3) were the most effective approaches for managing their fatigue.</p></div><div><h3>Conclusion</h3><p>Tools are needed to support HCPs with counseling patients with PC for effective management of disease- and treatment-related fatigue.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102209"},"PeriodicalIF":2.3,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paraneoplastic Syndrome Prevalence and Survival in Racially-Diverse Cohort With Renal Cell Carcinoma","authors":"Edouard H. Nicaise ,&nbsp;Benjamin N. Schmeusser ,&nbsp;Gregory Palmateer ,&nbsp;Khushali Vashi ,&nbsp;Krishna Parikh ,&nbsp;Dattatraya Patil ,&nbsp;Daniel D. Shapiro ,&nbsp;E. Jason Abel ,&nbsp;Shreyas Joshi ,&nbsp;Vikram Narayan ,&nbsp;Kenneth Ogan ,&nbsp;Viraj A. Master","doi":"10.1016/j.clgc.2024.102207","DOIUrl":"10.1016/j.clgc.2024.102207","url":null,"abstract":"<div><h3>Introduction</h3><p>The prevalence of preoperative paraneoplastic syndromes (PNS) in renal cell carcinoma (RCC) is poorly understood. Many laboratory abnormalities representative of PNS have demonstrated prognostic value when incorporated into predictive survival models in RCC. We sought to characterize the relationship between baseline prevalence of PNS with overall survival (OS) and cancer-specific survival (CSS) in RCC patients following nephrectomy.</p></div><div><h3>Methods</h3><p>Our prospectively maintained nephrectomy database was retrospectively reviewed for any stage, major histology RCC patients that underwent surgery from 2000 to 2022. Baseline laboratory values within 90 days (closest used) were required. Presence of PNS was defined according to established laboratory cutoffs. Kaplan-Meier curves estimated survival rates, and multivariable Cox proportional hazards models examined the association between PNS with OS and CSS following nephrectomy.</p></div><div><h3>Results</h3><p>2599 patients were included with listed staging: 1494 Stage I; 180 Stage II; 616 Stage III; 306 Stage IV. Proportion of patients presenting with &gt;1 PNS significantly increased from stage I (31.3%) to stage IV (74.2%) RCC (<em>P</em> &lt; .001). Elevated C-reactive protein was the most prevalent PNS (45.4%). On multivariable analysis, the presence of &gt;1 PNS was associated with higher risk of all-cause (HR 2.09; <em>P</em> &lt; .001) and cancer-specific mortality (HR 2.55; <em>P</em> &lt; .001). The 10-year OS estimates as reported: 65.2% (no PNS), 52.3% (1 PNS), 36.6% (&gt;1 PNS); and 10-year CSS estimates: 88.3% (no PNS), 79.3% (1 PNS), 61.6% (&gt;1 PNS).</p></div><div><h3>Discussion</h3><p>Increased prevalence of PNS in major histology RCC was associated with a significant increase in the risk of all-cause and cancer-specific mortality even when accounting for patient and disease characteristics.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102207"},"PeriodicalIF":2.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance","authors":"Marlon Perera ,&nbsp;Melissa Assel ,&nbsp;Sunny Nalavenkata ,&nbsp;Sari Khaleel ,&nbsp;Nicole Benfante ,&nbsp;Sigrid V. Carlsson ,&nbsp;Victor E. Reuter ,&nbsp;Vincent P. Laudone ,&nbsp;Peter T. Scardino ,&nbsp;Karim A. Touijer ,&nbsp;James A. Eastham ,&nbsp;Andrew J. Vickers ,&nbsp;Samson W. Fine ,&nbsp;Behfar Ehdaie","doi":"10.1016/j.clgc.2024.102204","DOIUrl":"10.1016/j.clgc.2024.102204","url":null,"abstract":"<div><h3>Background</h3><p>During active surveillance (AS) for Grade Group (GG) 2 prostate cancer, pathologic progression to GG3 on surveillance biopsy is a trigger for intervention. However, this ratio of GP3:GP4, may be obscured by increases of relatively indolent disease. We aimed to explore changes in GP4 quantity during AS and propose alternative definitions for progression based on GP4 changes.</p></div><div><h3>Design, Setting, and Participants</h3><p>We assessed patients enrolled on AS between November 2014 and March 2020 with GG2 disease on diagnostic biopsy and subsequent surveillance biopsy approximately 1 year later. Outcome measures included change in overall %GP4 and total length GP4 (mm).</p></div><div><h3>Results and Limitations</h3><p>61 patients met the inclusion criteria, the median change in total length of GP4 and %GP4 was -0.12 mm (IQR −0.31, 0.09) and −2.5% (IQR −8.6, 0.0), respectively. Excluding the 35 patients with no evidence of GP4 on surveillance biopsy, median change in total GP4 length and %GP4 was 0.19 mm (IQR −0.04, 0.67) and 1.2% (IQR −1.6, 6.6), respectively. Three patients progressed to GG3 disease on surveillance biopsy, one of whom had only a small increase in %GP4. Conversely, an additional 2 patients who did not meet the criterion for GG3 had a large increase (&gt; 1 mm) in total GP4 length.</p></div><div><h3>Conclusions</h3><p>Presence of GG3 disease on surveillance biopsy as a trigger for treatment in men on AS is of questionable use alone; we suggest including other measures that do not depend on a ratio, such as an increase in total GP4 length.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102204"},"PeriodicalIF":2.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1558767324001745/pdfft?md5=964b906d2822262977d032e605ab41b7&pid=1-s2.0-S1558767324001745-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Patients With Urogenital Cancer Rely on Artificial Intelligence Chatbots for Treatment Decisions?","authors":"Anil Erkan ,&nbsp;Akif Koc ,&nbsp;Deniz Barali ,&nbsp;Atilla Satir ,&nbsp;Salim Zengin ,&nbsp;Metin Kilic ,&nbsp;Gokce Dundar ,&nbsp;Muhammet Guzelsoy","doi":"10.1016/j.clgc.2024.102206","DOIUrl":"10.1016/j.clgc.2024.102206","url":null,"abstract":"<div><h3>Objectives</h3><p>In the era of artificial intelligence, almost half of the patients use the internet to get information about their diseases. Our study aims to demonstrate the reliability of the information provided by artificial intelligence chatbots (AICs) about urogenital cancer treatments.</p></div><div><h3>Methods</h3><p>The most frequently searched keyword about prostate, bladder, kidney, and testicular cancer treatment via Google Trends was asked to 3 different AICs (ChatGPT, Gemini, Copilot). The answers were evaluated by 5 different examiners in terms of readability, understandability, actionability, reliability, and transparency.</p></div><div><h3>Results</h3><p>The DISCERN score evaluation indicates that ChatGPT and Gemini provided moderate quality information, while Copilot's quality was low. (Total DISCERN scores; 41, 42, 35, respectively). PEMAT-P Understandability scores were low (40%) and PEMAT-P Actionability scores were moderate only for Gemini (60%) and low for the others (40%). Their readability according to the Coleman-Liau index was above the college level (16.9, 17.2, 16, respectively).</p></div><div><h3>Conclusions</h3><p>In the era of artificial intelligence, patients will inevitably use AICs due to their easy and fast accessibility. However, patients need to recognize that AICs do not provide stage-specific treatment options, but only moderate-quality, low-reliability information about the disease, as well as information that is very difficult to read.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102206"},"PeriodicalIF":2.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142136650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare type of Bellini Duct Carcinoma in a Patient With Cacchi–Ricci Disease: A Case Report and Mini-Review","authors":"Antonio Franco ,&nbsp;Thomas Tailly ,&nbsp;Camille Berquin ,&nbsp;Daan De Maeseneer ,&nbsp;Alexander Decruyenaere ,&nbsp;Sofie Verbeke ,&nbsp;Pieter De Visschere ,&nbsp;Kathia De Man ,&nbsp;Laurens Hermie ,&nbsp;Ben Vanneste ,&nbsp;Charles Van Praet","doi":"10.1016/j.clgc.2024.102202","DOIUrl":"10.1016/j.clgc.2024.102202","url":null,"abstract":"<div><p>Medullary sponge kidney (MSK) is an uncommon kidney malformation, characterized by cystic dilatation of the precalyceal papillary collecting ducts. Urography and computed tomography scan represent the gold standard to detect this congenital disorder. A clear diagnosis is not always feasible, especially in the presence of a concomitant renal mass, which in turn can be difficult to detect in MSK patients. When conventional imaging is inconclusive, a renal biopsy can be considered in doubtful cases. Here, we report a unique case of a Bellini duct carcinoma in a patient with MSK and we review the literature on this complex condition.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102202"},"PeriodicalIF":2.3,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142201661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}